CN103415619B - 抗-c-met抗体及其使用方法 - Google Patents
抗-c-met抗体及其使用方法 Download PDFInfo
- Publication number
- CN103415619B CN103415619B CN201180052705.2A CN201180052705A CN103415619B CN 103415619 B CN103415619 B CN 103415619B CN 201180052705 A CN201180052705 A CN 201180052705A CN 103415619 B CN103415619 B CN 103415619B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cell
- met
- cancer
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40278810P | 2010-09-03 | 2010-09-03 | |
US61/402,788 | 2010-09-03 | ||
PCT/US2011/049763 WO2012030842A2 (en) | 2010-09-03 | 2011-08-30 | Anti-c-met antibody and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103415619A CN103415619A (zh) | 2013-11-27 |
CN103415619B true CN103415619B (zh) | 2015-10-14 |
Family
ID=45773480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180052705.2A Active CN103415619B (zh) | 2010-09-03 | 2011-08-30 | 抗-c-met抗体及其使用方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9150655B2 (zh) |
EP (1) | EP2611928B1 (zh) |
JP (1) | JP5955322B2 (zh) |
KR (1) | KR20140019284A (zh) |
CN (1) | CN103415619B (zh) |
AU (1) | AU2011296085A1 (zh) |
CA (1) | CA2809677A1 (zh) |
RU (1) | RU2013114783A (zh) |
SG (1) | SG188324A1 (zh) |
TW (1) | TWI523867B (zh) |
WO (1) | WO2012030842A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10377827B2 (en) | 2012-06-21 | 2019-08-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
CN107613974B (zh) | 2015-03-16 | 2021-01-15 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
CN107531789B (zh) * | 2015-04-14 | 2021-08-10 | 中央研究院 | 用于抗血管新生和标靶癌症治疗的抗vegfr2人类抗体 |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
KR102433184B1 (ko) * | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
CN114340684A (zh) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
MXPA05008521A (es) | 2003-02-13 | 2005-10-20 | Pharmacia Corp | Anticuerpos a c-met para el tratamiento de canceres. |
EP1761563A4 (en) | 2004-05-10 | 2008-05-14 | Macrogenics Inc | HUMANIZED gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE |
US7749485B2 (en) | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
CN104804095A (zh) * | 2004-08-05 | 2015-07-29 | 健泰科生物技术公司 | 人源化抗c-met 拮抗剂 |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
AU2007213804B2 (en) * | 2006-02-06 | 2012-12-13 | Vertical Bio Ag | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
CN101415730B (zh) * | 2006-03-30 | 2013-04-10 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
TW201019961A (en) | 2008-10-17 | 2010-06-01 | Genentech Inc | Combination therapy |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
AU2011261161A1 (en) | 2010-06-01 | 2013-01-10 | Ludwig Institute For Cancer Research Limited | Antibodies directed to the unprocessed receptor tyrosine kinase c-Met |
-
2011
- 2011-08-30 WO PCT/US2011/049763 patent/WO2012030842A2/en active Application Filing
- 2011-08-30 CA CA2809677A patent/CA2809677A1/en not_active Abandoned
- 2011-08-30 RU RU2013114783/10A patent/RU2013114783A/ru unknown
- 2011-08-30 US US13/818,283 patent/US9150655B2/en not_active Expired - Fee Related
- 2011-08-30 CN CN201180052705.2A patent/CN103415619B/zh active Active
- 2011-08-30 AU AU2011296085A patent/AU2011296085A1/en not_active Abandoned
- 2011-08-30 JP JP2013527228A patent/JP5955322B2/ja not_active Expired - Fee Related
- 2011-08-30 KR KR1020137007635A patent/KR20140019284A/ko not_active Application Discontinuation
- 2011-08-30 EP EP11822500.2A patent/EP2611928B1/en active Active
- 2011-08-30 SG SG2013014832A patent/SG188324A1/en unknown
- 2011-09-02 TW TW100131790A patent/TWI523867B/zh not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment;Cheng WW1, Allen TM.;《Expert Opin Drug Deliv.》;20100430;第7卷(第4期);摘要,第1节第1、3段,第1.1、1.2、1.4节,图1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2611928A4 (en) | 2014-05-14 |
JP5955322B2 (ja) | 2016-07-20 |
RU2013114783A (ru) | 2014-10-10 |
TWI523867B (zh) | 2016-03-01 |
CN103415619A (zh) | 2013-11-27 |
CA2809677A1 (en) | 2012-03-08 |
EP2611928A1 (en) | 2013-07-10 |
SG188324A1 (en) | 2013-04-30 |
AU2011296085A1 (en) | 2013-03-28 |
EP2611928B1 (en) | 2016-04-27 |
KR20140019284A (ko) | 2014-02-14 |
US20130209365A1 (en) | 2013-08-15 |
JP2013543375A (ja) | 2013-12-05 |
US9150655B2 (en) | 2015-10-06 |
WO2012030842A2 (en) | 2012-03-08 |
TW201241007A (en) | 2012-10-16 |
WO2012030842A8 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI726879B (zh) | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 | |
US9670287B2 (en) | Anti-human TROP-2 antibody having anti-tumor activity in vivo | |
CN103415619B (zh) | 抗-c-met抗体及其使用方法 | |
ES2484842T3 (es) | Anticuerpo anti-DLK-1 humana que muestra la actividad antitumoral in vivo | |
CN104114580B (zh) | 在体内具有抗肿瘤活性的抗人trop‑2抗体 | |
JP2020511130A (ja) | Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法 | |
JP2022512124A (ja) | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 | |
CN107135654A (zh) | 巨胞饮人类抗cd46抗体和靶向癌症疗法 | |
JP2020532509A (ja) | 活性化可能抗cd166抗体およびその使用方法 | |
US20220023439A1 (en) | Activatable anti-cd166 antibodies and methods of use thereof | |
WO2017196847A1 (en) | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens | |
US9029509B2 (en) | Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR) | |
CN106432495A (zh) | 抗肿瘤抗原抗体及其使用方法 | |
CN103596985A (zh) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 | |
US20220064324A1 (en) | Cross species single domain antibodies targeting mesothelin for treating solid tumors | |
JP2022023078A (ja) | Muc1に特異的に結合する抗体及びその用途 | |
JP6938478B2 (ja) | 癌幹細胞を阻害する組成物及び方法 | |
WO2021251459A1 (ja) | ヒト化抗gpc-1抗体 | |
WO2021251460A1 (ja) | Cafを有するがんを処置するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150915 Address after: China Taiwan Nangang District Taipei City Applicant after: Academia Sinica Address before: China Taiwan Nangang District Taipei City Applicant before: Academia Sinica Applicant before: Liang Qiming |
|
CB03 | Change of inventor or designer information |
Inventor after: Wu Hanzhong Inventor after: Lv Ruimin Inventor before: Wu Hanzhong Inventor before: Lv Ruimin Inventor before: Liang Qiming |
|
COR | Change of bibliographic data |